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Objective:  The goal of this study was to get a better understanding the role of Power Doppler (PDUS)
and conventional Gray Scale transrectal ultrasound (TRUS) in targeting prostatic biopsy in men with high
prostate-specific antigen (PSA).
Patients  and  methods:  A prospective comparative study of 100 men, categorized according to PSA level into
two groups: Group (A) with a PSA level (4.0–10.0) ng/ml (Gray zone) and Group (B) with PSA >10.0 ng/ml,
above Gray zone. Gray Scale scanning was done, followed by Color Doppler and Power Doppler to test the
blood flow all over the prostate and suspicious foci. Twelve systematic TRUS-guided core needle biopsies
were performed, and additional biopsies of abnormal lesions on Gray Scale TRUS and PD-TRUS. The
demographic data, clinical data, imaging results, laboratory investigations, histopathological report and its
correlation with pathological results and any complications during or post the procedure estimated.
Results:  The age of the Group (A) ranged between 50 and 75 years with a mean ±  S.D. of 65.7 ±  6.8 years,
while in the Group (B), it ranged between 54 and 84 years with a mean ±  S.D. of 69.5 ±  6.3 years. TRUS
biopsy revealed prostate cancer in 11 (35.5%) out of 31 cases of the Group (A) and 35 (50.7%) out of 69
cases of the Group (B) (p  < 0.003). Thirty out of 39 (76.9%) from Group (B) were hypervascular in PDUS
ositive predictive value (PPV) and negative predictive values were 74.5%,
(p < 0.04).
PDUS sensitivity, specificity, p
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Conclusion:  Power Doppler ultrasonography (PDUS) increase the cancer detection rate diagnosis, PDUS
combination with Gray Scale TRUS-guided biopsy increases the reliability of the diagnosis of cancer
prostate.
© 2018 Pan African Urological Surgeons Association. Production and hosting by Elsevier B.V. This is an open






















































































olor flow Doppler (CFD) and Power Doppler imaging (PDI)
dvanced and have accepted as a tool for prostatic carcinoma diag-
osis. Vascularity assessment has two methods of using PDI: total
ascularity (TV) and vascular density (VD), and estimate whether
uantitative Doppler vascularity correlated with prostate cancer
etection. They postulated that the gross total number of blood
essels (TV) in the prostate is diagnostic than the vascular den-
ity (VD) [1]. Histology literature integrates angiogenesis in cancer
hrough using vessel density (number of vessels per unit area of the
issue) to ass’s vascular activity. A series intended to understand
he differences between TV and VD of the prostate and to evalu-
te their correlation to pathologic diagnosis. They review how TV
nd VD correlate with visual evaluation of vascularity on Doppler
mages, how TV and VD vary from the central zone versus peripheral
one, and, whether the differences in Doppler TV or VD be used
o differentiate the prostatic lesions, especially, adenocarcinoma,
enign prostatic hypertrophy (BPH) as well as intraepithelial neo-
lasia (PIN) [2]. Hypervascularity correlated with prostate cancer
ue to increased angiogenesis [3]. TRUS has a high sensitivity but
ssociated with a low positive predictive value (PPV) in the diagno-
is of early malignant lesions, which lowering its strength, because
ypoechoic lesions detected in a benign lesion. Various modalities
nvestigated to reduce the cost and morbidity and to avoid unnec-
ssary biopsies. Hypoechoic lesion on Gray Scale ultrasound only
as a deficiency in the diagnosis of the most prostate malignancies
4]. Color and Power Doppler ultrasound and Gray Scale TRUS
hen used together, they will increase the sensitivity of detecting
rostate cancer, but the specificity is not decreasing. So, the lesions
hich seem positive Color and Power Doppler ultrasound findings
re significant for cancer detection [5].
he goal of this study was to get a better understanding the role
f Power Doppler (PDUS) and conventional transrectal ultrasound
Gray Scale TRUS) in targeting Prostatic lesion in a patient with
igh prostate-specific-antigen (PSA).
atients  and  methods
rospective comparative study of one hundred men from outpatient
linics of Urology and Ultrasonography Unit Al-Azhar Univer-
ity Hospitals in the period between November 2012 and May
015. After approval of the Medical Research Ethical Committee,
n informed written consent obtained. Patients were categorized
ccording to serum prostate - specific antigen as two groups,
roup(A)with a PSA level (4.0 -10.0) ng/ml. (Gray Zone), and
roup (B), with PSA >10.0 ng/ml, above Gray Zone, included in this





he examination; infection controlled. Patients on anticoagulant
herapy are not a candid for examination until the anticoagu-
ant dosage adjusted. Also, patients on finasteride therapy were
xcluded.
ne day before examination patient received levofloxacin 750 mg
nce daily and metronidazole 500 mg three times per day, to
ontinue for two days after the procedure. A cleansing enema per-
ormed before the procedure. And non-steroidal anti-inflammatory
NSAIDS) and aspirin stopped for 3 and 5 days before the procedure.
he procedure performed by using transrectal ultrasound (TRUS
ray Scale and Power Doppler) (B&K Medical, Denmark). Tran-
rectal imaging of the prostate completed by using an endocavitary
ransducer (A 5.0–7.5 MHz). Gray Scale scans are done to the pro-
tatic tissue in the axial and sagittal sections in all patients and its
djacent structures to detect any suspicious lesion (presence of an
rregular contour and an asymmetric gland recorded as an abnormal
nding). With TRUS, the prostate categorized into a peripheral zone
isoechoic) and a heterogeneous central gland, (transition zone).
alcifications (corpora amylacea) are common at the boundary
etween the peripheral zone and the central gland. The seminal vesi-
les visualized as convoluted hypoechoic cystic structures. Prostate
ancers visualized as hypoechoic lesions within the isoechoic nor-
al peripheral zone, but lesions appear as isoechoic, hyperechoic,
r multifocal as well as TRUS, which recorded.
olor Doppler and Power Doppler ultrasound used to estimate the
lood flow among the prostatic tissue and suspicious lesion. The
ignals from Color Doppler classified into normal vascular, hypo-
ascular and hypervascular foci. Grading of PDUS categorized as
ollows: Grade 0, no abnormal vascularity; Grade 1, low focal vas-
ular clustering; Grade 2, intensive focal vascular clustering; and
rade 3, diffuse vascular clustering.
welve core biopsies taken using TRUS-guided needle biopsies by
n 18-gauge biopsy cutting needle driven through a biopsy gun.
xtra biopsies from areas that showed abnormality (hypoechoic or
ypervascular lesion). Management of complications if occurred,
uring and after the procedure and evaluation of the histopatholog-
cal examination reports and the data collected for analysis.
tatistical  analysis
he data analyzed using statistical package for social science
SPSS version 20.0) for Windows (SPSS IBM: Chicago, IL). The
esults expressed as mean ±  SD with 95% confidence interval by
sing medians for quantitative variables, and using the frequencies




















































Hypoechoic versus hypervascular lesion in the diagnosis of prostati
tically significant. Sensitivity, specificity, positive predictive value
(PPV) and the negative predictive value estimated by using Med-
Calc1 V.7.1.0.1. Student-t-test used to compare the parametric data
between the groups
Results
The age of Group (A) ranged between 50 and 75 years with a
mean ±  S.D. of 65.7 ±  6.8 years. While in Group (B), it ranged
between 54 and 84 years with a mean S.D. of 69.5 ±  6.3 years. So,
the mean age was higher in Group (B) than in group A (p  = 0.01).
Serum PSA of Group (A) (Gray zone) ranged between 4.5 and
10 ng/dl with a mean ±  S.D. of 7.9 ±  1.4 ng/dl, while in Group (B)
above Gray zone, it ranged between 10.5 and more than 1000 ng/dl
with a mean ±  S.D. of 66.4 ±  145 ng/dl.
Digital rectal examination (DRE), 22.6% of the Group (A) and
40.6% of the Group (B) had an abnormal DRE which was statisti-
cally significant (p  = 0.04).
TRUS biopsy revealed prostate cancer in 11 (35.5%) out of 31 cases
of the Group (A) and 35 (50.7%) out of 69 cases of Group (B).
Correlation between the results of the DRE and histopathological
examination revealed a statistically significant difference (p  = 0.04).
TRUS revealed hypoechoic lesions in 40 cases, 12 out of them were
of the Group (A) and 28 were of the Group (B). So, there was
no statistically significant difference in hypoechoic lesion detection
between the two study groups (38.7% for Group (A) vs. 40% for
Group (B)) (p  = 0.6).
Histopathological examination of cores taken from hypoechoic
lesions revealed adenocarcinoma in 24 cases (6 out of them were of
Group (A) and 18 were of Group (B)). So, cancer detected in 50%
(6/12) of hypoechoic lesions in Group (A) and in 64.3% (18/28)
of Group (B). Which was statistically significant (p  = 0.006). Com-
parative study of the groups, depending on adenocarcinoma of a
hypoechoic lesion, we find a statistical difference with (p-value
<0.01) 25% of patients of a hypoechoic lesion in the Group (A)
and 75% in the Group (B).
Color Doppler showed hypervascularity in 51 (51%) patients (15 out
of them were of Group (A) and 36 were of Group (B)). The difference
between both groups is statistically insignificant (p  = 0.7).
Correlation between the cores taken from hypervascular areas and
the results of histopathology revealed that cancer detected in 38 out
of 51 (74.5%) hypervascular areas (8 out of them were of Group (A)
and 30 were of Group (B)). So, an incidence of cancer detection in
hypervascular areas in Group (B) (83.3%) was higher than Group
(A) (53.3%) which was statistically significant (p  = 0.02).
Through these criteria, patients who had a hypoechoic and hyper-
vascular lesions cross-tabulated with adenocarcinoma, we find a
highly significant difference in the incidence of adenocarcinoma
between hypoechoic, hypervascular lesions than in hypoechoic non-







imilarly, as well as we find (p-value <0.001) in patients with
on-hypoechoic and hypervascular Lesions cross-tabulated with
denocarcinoma according to histopathology, that meant there was
 highly significant difference in the incidence of adenocarcinoma
mong non-hypoechoic hypervascular lesions than non-hypoechoic,
on-hypervascular lesions according to the histopathology (p-value
.01) (Tables 1 and 2).
DUS guided biopsies missed three cases, one of which appeared as
 non-vascular, non-hypoechoic in Gray Scale TRUS in the Group
A). The other two adenocarcinoma cases were neither hypoechoic
n Gray Scale TRUS nor hypervascular in PDUS in the Group (B).
he three missed cases demonstrated with systematic TRUS biopsy.
ccording to hypervascularity grading, 51 cases diagnosed, 15 from
roup (A) and 36 from Group (B) out of the 38 patients diagnosed
s adenocarcinoma (3 G0 7.9%, 7/38 18.47% G1, 10/38 26.3% G2
nd 18/38 47.3 G3) (Fig. 1A–C).
ower Doppler Ultrasound (PDUS) sensitivity, specificity, positive
redictive value (PPV) and negative predictive values were 74.5%,
5.7%, 84.4% and 76.4%, respectively. PDUS had greater sensitiv-
ty and specificity than TRUS (60% and 66.7%, respectively) and
dentified cancer cases more accurately (Table 3).
iscussion
he most commonly used methods for detection of prostatic car-
inoma is the conventional transrectal ultrasound (TRUS-guided
rostate biopsy). TRUS has several benefits including safety,
ortability, low-cost, and the ability to do real-time imaging and
mage-guided procedures in an office setting. A hypoechoic lesion
hich appears on the Gray Scale ultrasound, is the most common
ppearance of prostate cancer, but it is isoechoic in up to 30%
f patients. One study compared GSU and PDU with 620 radi-
al prostatectomy specimens and revealed combination of PDU and
SU make efficient specificity from 47 to 74% [6].
n this work, Gray Scale scanning performed for 100 patients all
ver the entire prostatic tissue, as well as the surrounding structures
o look for areas that appear suspicious. The Gray Scale assessment
n our study shows that 40 (40%) patients had hypoechoic lesions,
2 (30%) patients in Gray zone of PSA (Group (A)) and 28 (70%)
atient above Gray zone (Group (B)). The results of the histopatho-
ogical examination of the biopsies showed adenocarcinoma in 24
60%) patients from patients with hypoechoic lesions and 24 (24%)
atients from the total number of all patients. Six (25%) patients
ere in the Gray zone and, 18 (75%) patients above the Gray zone.
hen we used Color and Power Doppler US in our series, we found
1 (51%) patients with hypervascular lesions, 15 (29%) patients in
he Gray zone and 36 (71%) patient above Gray zone, the results
f the histopathological examination of the biopsies detect adeno-
arcinoma in 38 (74.5%) patients from patients with hypervascular
esions and 8 (21%) patients in the Gray zone and 30 (79%) patients
bove Gray zone [7].
he hypoechoic lesions which appeared on Gray Scale ultrasound
ay appear hypervascular or non-hypervascular and hypervas-
ular lesions which appeared in PDUS may be hypoechoic
r non-hypoechoic. So, we have four characters for prostatic
esions, hypoechoic, hypervascular lesions (23 patients), hypoe-
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Table  1  Correlation between Gray Scale, Power Doppler and histopathology in Group (A).
Adeno. = adenocarcino, BPH = benign prostatic hyperplasia, PIN = prostatic intraepithelial neoplasia.
Table  2  Correlation between Gray Scale, Power Doppler and Histopathology in Group (B).
Fig.  1  Color, Power Doppler and Gray Scale transrectal ultrasound. (A) Color scale ultrasound (hypervasculer lesion). (B) Gray Scale ultra-
sound (no hypoechoic lesion). (C) Power Doppler ultrasound (hypervasculer lesion). PSA, 13.4 ng/ml. Pathology: poorly differentiated prostatic
adenocarcinoma, Gleason score 9 (5 + 4).
Hypoechoic versus hypervascular lesion in the diagnosis of prostatic carcinoma 173
Table  3  Sensitivity, specificity, PPV, NPV of Gray Scale TRUS and PDUS methods.
PPV = positive predictive value, NPV = negative predictive value.





















choic, non-hypervascular lesions (17 patients), hypervascular,
isoechoic lesions (28 patients) and isoechoic, non-hypervascular
prostate (32 patients).
The sensitivity of GSU for prospective tumor detection varies by
experience has reported up to 60% of tumors appear hypoechoic,
isoechoic in 35–39%, which is a limitation on Gray Scale ultrasound
cancer detection rate [8].
When using Gray Scale and Doppler ultrasound in our study, we
found 67 (67%) patients with lesions, whether hypoechoic, hyper-
vascular or hypoechoic only or hypervascular only. The results of
the histopathological examination of the biopsies detect adenocarci-
noma in 43 (64.2%) in patients with lesions (i.e. 43% patients from
the total number of study patients). Ten (23.2%) patients out of them
were in the Gray zone and 33 (76.7%) patients were above the Gray
zone. Prostatic adenocarcinoma incidence in lesions which have the
two characters hypoechoic, hypervascular were 19 patients from 23
patients (82.6%).
Power Doppler ultrasound is sensitive as to detect flow in vessels
as small as 1 mm, asymmetrically increased flow patterns of the
tumor with a significant increase in the number and size of vessels
suggesting prostate cancer on Doppler imaging. These vessels will
show an irregular orientation in contrast to the typical radial pat-
C
w
ern of normal prostate flow [9]. The sensitivity of Gray Scale in
ur study was 60%, which lies in the range found in the literature
8–88%). The specificity was 86.7%, which bring a closer figure
o that reported by Kuligowska et al. [10], 85%. The PPV (posi-
ive predictive value) was 75% and NPV (negative predictive value)
as 76.5%, which agree with that mentioned by Russo et al. [10]
2% and 79% respectively. The sensitivity of the combined Gray
cale and Doppler together in our study was 74.5%, specificity
as 85.7%, and PPV (positive predictive value) was 84.4%. So,
e recommend using the two modalities, Gray Scale, and Doppler
n targeting prostatic biopsies and once hypoechoic, hypervascular
esions appeared, an additionally directed biopsy performed.
DUS has the usefulness over CDUS of detecting very low vascular
ows, to get better cancer detection rates with TRUS-guided biopsy
aken from abnormal vascular foci [9].
adhakrishnan and Vinodh [11] prove that high-test performance
f PDUS for prostate cancer diagnosis with 98% sensitivity and
 99% NPV. Some studies have reported that Power Doppler is a
ependable method for prostate cancer detection and propose that
t can also predict the tumor aggressiveness [12,13].olor and Power Doppler US in our study, we found 51 (51%) cases


































































[15] Takahashi S, Yamada Y, Homma Y. Power Doppler US-directed
prostate biopsy in men with elevated serum PSA levels. Urology
2002;60:248–52.74 
6 (71%) patient above Gray zone, the results of the histopathologi-
al examination of the biopsies show adenocarcinoma in 38 (74.5%)
atients from the total number of patients with hypervascular lesions
nd 38 (38%) cases from all patients. Eight (21%) patients in the
ray zone and 30 (79%) patients above the Gray zone.
n our study, as well as in others [14], there was a highly significant
ositive correlation between PSA and age (p  = 0.004).
he sensitivity of the DRE increased when PSA is high, 20% if the
SA level less than 3.0 ng/ml. While the sensitivity of the DRE
ecame 46% PSA level was 10 ng/ml or more [15]. Our study
howed a highly significant positive correlation between abnormal
RE and prostate cancer in different studied groups, in the Group
B) incidence of prostate cancer increased with abnormal DRE than
roup (A).
hen examining any technique is better than the other according
o the Modalities to take Biopsy, we found significant deference
ncreased direction of using the two techniques together {Gray
cale, Color and Power Doppler (Hypoechoic and Hypervascu-
ar)}. Out of 68 patients harboring lesions either Hypoechoic or
ypervascular or both 43 patients diagnosed as adenocarcinoma
63.2%), while 3 cases out of 32 had no lesions diagnosed with can-
er prostate (9.3%), p-value of 0.03. So, the percentage of systematic
ore biopsy for total patients diagnosed with cancer, prostate was
3/46 = 6.52%), as presented in Table 4.
ur recommendations are using Gray Scale and Doppler as a com-
ined modality in targeting prostatic biopsies and any lesion either
ypoechoic or hypervascularity estimated and a biopsy should take,
n addition to the twelve core biopsies which taken as sextant biopsy.
lso, we recommend any active urinary tract infection be treated
efore any manipulations. Patient with finasteride therapy is not a
andidate for Doppler examination because one of the mechanisms
f action of this drug is the decrease of vascularity.
imitations  of  the  study
 small number of patient of this study in which 100 patients studied.
lso, a prostatic biopsy was not marked separately to show which
ore is positive and percentage of cancer in each core.
onclusion
ower Doppler ultrasonography (PDUS) increases the cancer detec-
ion rate diagnosis. The diagnostic reliability of cancer prostate
ncreased by a combination of PDUS with Gray Scale TRUS-guided
iopsy. However, twelve core biopsies continued as the best diag-
ostic modality.
uthors’  contributions
bdel-naby Saed Elshamy – Collection and data analysis of patho-
ogical parameters.thical  approval
l-Azhar Medical Research Ethics committee.A.I. Ebeid, A.S. Elshamy
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